Financial Data and Key Metrics Changes - The company's revenue for 2025 was $761 million, an increase from $675 million in the previous year, with a revenue guidance for 2026 set at $900 million to $1 billion [3][4] - Net income for 2025 was $99.7 million, down from $141.2 million in the prior year [3] Business Line Data and Key Metrics Changes - The Cushing's syndrome business saw a 37% increase in tablet deliveries compared to 2024, with a record number of new prescriptions and first-time prescribers [11][12] - Despite a 61% increase in new prescriptions, the gap between new prescriptions and tablets sold indicates capacity issues with the pharmacy vendor [11] Market Data and Key Metrics Changes - The company transitioned to a new specialty pharmacy in October 2025 to address capacity issues, which has shown promising signs of improved performance [12][56] - The Cushing's syndrome business is expected to grow to at least $2 billion in annual revenue by the end of the decade, driven by increased recognition of hypercortisolism [14][26] Company Strategy and Development Direction - The company plans to appeal the recent court ruling against its patent for Korlym and is focused on making relacorilant available to patients as quickly as possible [4][10] - The company is optimistic about the potential of relacorilant in treating various solid tumors and is exploring its use in combination with other anticancer therapies [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed surprise at the FDA's decision not to approve relacorilant, citing strong clinical trial data and a history of collaboration with the FDA [5][10] - The company is confident in its future growth, particularly in the Cushing's syndrome market, and anticipates significant demand as findings from recent studies are recognized by physicians [26][28] Other Important Information - The company reported cash and investments of $532 million as of December 31, 2025, reflecting a stock repurchase program [4] - The ROSELLA trial demonstrated a 35% reduction in the risk of death for patients receiving relacorilant in combination with nab-paclitaxel, with a median overall survival increase of 4.1 months [19][20] Q&A Session Questions and Answers Question: Thoughts on the CRL and future trials for relacorilant - Management believes the FDA may have shifted its expectations and plans to clarify this in an upcoming meeting [30][34] - The company is considering running a randomized trial for relacorilant in type 2 diabetes and hypertensive patients, but no definitive path has been established yet [41] Question: Guidance assumptions for Korlym - The net price for Korlym through the AG is about a 30% discount, with expectations for 2026 indicating a stabilization in pricing pressures [31][40] Question: Supply chain issues and safety data - The transition to a new pharmacy partner has improved metrics, and management is confident in their ability to meet future demand [55][56] - Safety data from the ROSELLA trial shows no significant increases in ALT levels compared to nab-paclitaxel alone, indicating a favorable safety profile [60][62] Question: Impact of KEYTRUDA on the market - Management noted that KEYTRUDA's approval is limited to specific biomarker expressions, and there is interest in maintaining treatment options for patients [64]

Core Insights - The article discusses the impact of cortisol on human health, emphasizing that while cortisol is essential for survival, its prolonged elevation due to modern stressors can lead to significant health issues [2][4]. Group 1: Understanding Cortisol - Cortisol is a complex chemical messenger that helps humans respond to threats, but its long-term elevation is linked to memory impairment, immune suppression, and various metabolic issues [2][4]. - The body's response to stress involves a precise neurobiological pathway, where the hypothalamus activates the hypothalamic-pituitary-adrenal axis, leading to cortisol release [3][4]. Group 2: Effects of Chronic Stress - Chronic elevation of cortisol can result in serious biological consequences, including decreased memory and executive function, changes in neuron structure, and widespread metabolic problems [4]. - The physiological structure of humans is not designed to cope with the long-term stress prevalent in modern life, which includes toxic productivity and information overload [4]. Group 3: Managing Cortisol Levels - Strategies to manage cortisol levels include cognitive reappraisal, strategic recovery, and regular exercise, which can help the body handle stress more effectively [5][8]. - Cognitive reappraisal involves changing the perception of stress, which can positively affect cardiovascular responses [8]. - Engaging in focused work followed by short breaks can help align with the body's natural cortisol rhythms, while moderate exercise is beneficial for cortisol regulation [8].